Aloxistatin

Drug Profile

Aloxistatin

Alternative Names: E 64 D; EST; Estate; Loxistatin; Rexostatine

Latest Information Update: 03 Apr 1996

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Taisho Pharmaceutical
  • Developer Sumitomo Pharmaceuticals; Taisho Pharmaceutical
  • Class Antineoplastics; Eye disorder therapies
  • Mechanism of Action Peptide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Muscular dystrophies

Most Recent Events

  • 03 Apr 1996 Discontinued-Clinical for Muscular dystrophy in Japan (Unknown route)
  • 28 Mar 1996 Investigation in Muscular dystrophy in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top